Short Sleep Duration Linked to All-Cause Mortality in Apnea Patients
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 5, 2023 -- For patients with obstructive sleep apnea (OSA), those sleeping less than seven hours have increased risk of all-cause mortality, according to a study published online Dec. 5 in JAMA Network Open.
Yiqi Lin, M.D., from Fujian Medical University in Fuzhou, China, and colleagues conducted a cohort study to examine whether there is an association between sleep duration and all-cause mortality among participants with OSA. Data were included for 2,574 individuals with OSA defined by apnea-hypopnea index (AHI) ≥15.
A total of 688 all-cause deaths were observed among the participants. The researchers found that the groups sleeping six to less than seven hours, five to less than six hours, and less than five hours had significantly higher risks of all-cause mortality, independent of AHI, compared with the group sleeping at least seven hours (hazard ratios, 1.53, 1.40, and 1.64, respectively). The finding was mainly consistent in sensitivity analyses performed among participants with available data of positive airway pressure treatment during follow-up.
"Further research would be needed to shed light on its underlying mechanism and possible health benefits of extending sleep length among people with OSA with short sleep duration by sleep education or other sleep intervention," the authors write.
One author disclosed ties to Eisai China Inc.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-12-06 04:37
Read more
- Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
- Transcatheter Valve Replacement Best for Severe Tricuspid Regurgitation
- ACG: Hormone Therapy Tied to Higher Risk for New Irritable Bowel Syndrome
- Even 'Weekend Warrior' Exercise Can Keep Your Brain Healthy
- UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024
- Burger King, Other Fast Food Chains Also Pulling Onions Tied to E. Coli Outbreak
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions